Wanhuida Intellectual Property

Wu Xiaoping of Wanhuida Intellectual Property comments on how hindsight bias contributed to an 'obviously erroneous’ ruling by the China National Intellectual Property Administration and welcomes the revised Guidelines for Patent Examination

Jianhui Li of Wanhuida Intellectual Property reports on a ruling by the China National Intellectual Property Administration that could shed light on the patent examination standards concerning cutting-edge siRNA inventions

Jicheng Yang of Wanhuida Intellectual Property explains the revised regulations concerning the adjustment and extension of patent terms

Minnan (Miranda) Xie of Wanhuida Intellectual Property provides a guide to drafting patent applications in the burgeoning area of personalised medicine and companion diagnostics, thereby avoiding the ineligibility pitfall and ensuring adequate protection

Two invalidation decisions involving the US pharmaceutical company provide guidance on the building of a patent portfolio in China and the filing of supplementary experimental evidence, says Yue Guan of Wanhuida Intellectual Property

Wu Xiaohui of Wanhuida Intellectual Property reports on an invalidation decision that demonstrates the importance of patentees limiting and generalising technical features in claims so that they can be sufficiently supported by the specification